EA023674B1 - Гетеродимерные связывающие белки и их применение - Google Patents

Info

Publication number

EA023674B1

EA023674B1 EA201290568A EA201290568A EA023674B1 EA 023674 B1 EA023674 B1 EA 023674B1 EA 201290568 A EA201290568 A EA 201290568A EA 201290568 A EA201290568 A EA 201290568A EA 023674 B1 EA023674 B1 EA 023674B1

Authority

EA

Eurasian Patent Office

Prior art keywords

region

polypeptide

domain

immunoglobulin

single chain

Prior art date

2009-12-29

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000833 heterodimer Substances 0.000 title claims abstract description 268
• 102000014914 Carrier Proteins Human genes 0.000 title description 2
• 108091008324 binding proteins Proteins 0.000 title description 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 834
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 822
• 229920001184 polypeptide Polymers 0.000 claims abstract description 817
• 230000027455 binding Effects 0.000 claims abstract description 460
• 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 309
• 102000018358 immunoglobulin Human genes 0.000 claims abstract description 309
• 238000005734 heterodimerization reaction Methods 0.000 claims abstract description 120
• 210000004027 cell Anatomy 0.000 claims abstract description 89
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 74
• 238000000034 method Methods 0.000 claims abstract description 50
• 201000011510 cancer Diseases 0.000 claims abstract description 43
• 230000001363 autoimmune Effects 0.000 claims abstract description 15
• 230000012010 growth Effects 0.000 claims abstract description 15
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
• 230000004968 inflammatory condition Effects 0.000 claims abstract description 5
• 241000282414 Homo sapiens Species 0.000 claims description 149
• 235000001014 amino acid Nutrition 0.000 claims description 148
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 148
• 150000001413 amino acids Chemical class 0.000 claims description 109
• 238000006467 substitution reaction Methods 0.000 claims description 82
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 57
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 40
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 40
• 239000000203 mixture Substances 0.000 claims description 32
• 239000000556 agonist Substances 0.000 claims description 29
• 208000035475 disorder Diseases 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 28
• 239000013604 expression vector Substances 0.000 claims description 19
• 230000015572 biosynthetic process Effects 0.000 claims description 18
• 239000005557 antagonist Substances 0.000 claims description 17
• 108090000174 Interleukin-10 Proteins 0.000 claims description 15
• 206010027476 Metastases Diseases 0.000 claims description 15
• 230000006510 metastatic growth Effects 0.000 claims description 15
• 235000018417 cysteine Nutrition 0.000 claims description 12
• 230000014509 gene expression Effects 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 230000004913 activation Effects 0.000 claims description 10
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
• 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 claims description 6
• 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 claims description 6
• 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 5
• 108010052199 HLA-C Antigens Proteins 0.000 claims description 5
• 108091033319 polynucleotide Proteins 0.000 claims description 5
• 102000040430 polynucleotide Human genes 0.000 claims description 5
• 239000002157 polynucleotide Substances 0.000 claims description 5
• 238000012258 culturing Methods 0.000 claims description 3
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
• 101000610400 Homo sapiens E3 ubiquitin-protein ligase TRIM37 Proteins 0.000 claims 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
• 101001095987 Homo sapiens RalBP1-associated Eps domain-containing protein 2 Proteins 0.000 claims 1
• 102100037884 RalBP1-associated Eps domain-containing protein 2 Human genes 0.000 claims 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
• 150000007523 nucleic acids Chemical class 0.000 abstract description 30
• 108020004707 nucleic acids Proteins 0.000 abstract description 23
• 102000039446 nucleic acids Human genes 0.000 abstract description 23
• 239000013598 vector Substances 0.000 abstract description 18
• 230000004927 fusion Effects 0.000 abstract description 7
• 239000007787 solid Substances 0.000 abstract description 7
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract description 3
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract description 3
• 230000036210 malignancy Effects 0.000 abstract description 3
• 230000006044 T cell activation Effects 0.000 abstract description 2
• 239000012634 fragment Substances 0.000 description 284
• 101000820585 Homo sapiens SUN domain-containing ossification factor Proteins 0.000 description 225
• 102100021651 SUN domain-containing ossification factor Human genes 0.000 description 225
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 115
• 229940024606 amino acid Drugs 0.000 description 114
• 239000000427 antigen Substances 0.000 description 37
• 102000036639 antigens Human genes 0.000 description 37
• 108091007433 antigens Proteins 0.000 description 37
• 108090000623 proteins and genes Proteins 0.000 description 36
• 125000000539 amino acid group Chemical group 0.000 description 35
• 235000018102 proteins Nutrition 0.000 description 35
• 102000004169 proteins and genes Human genes 0.000 description 35
• 102000005962 receptors Human genes 0.000 description 32
• 108020003175 receptors Proteins 0.000 description 32
• 230000035772 mutation Effects 0.000 description 29
• 101710147325 Calcineurin B homologous protein 3 Proteins 0.000 description 28
• 102100031077 Calcineurin B homologous protein 3 Human genes 0.000 description 28
• 235000004279 alanine Nutrition 0.000 description 24
• 230000003993 interaction Effects 0.000 description 22
• 210000004899 c-terminal region Anatomy 0.000 description 21
• 238000012217 deletion Methods 0.000 description 20
• 230000037430 deletion Effects 0.000 description 20
• 238000011282 treatment Methods 0.000 description 19
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 18
• 102000037865 fusion proteins Human genes 0.000 description 18
• 108020001507 fusion proteins Proteins 0.000 description 18
• -1 radioisotope Substances 0.000 description 17
• 208000023275 Autoimmune disease Diseases 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 15
• 239000003795 chemical substances by application Substances 0.000 description 15
• 230000006870 function Effects 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 13
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
• 101100484399 Human herpesvirus 7 (strain JI) U55A gene Proteins 0.000 description 12
• 230000013595 glycosylation Effects 0.000 description 12
• 238000006206 glycosylation reaction Methods 0.000 description 12
• 208000027866 inflammatory disease Diseases 0.000 description 12
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 102220493349 40S ribosomal protein S3_T70R_mutation Human genes 0.000 description 10
• 239000004475 Arginine Substances 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 10
• 229940072221 immunoglobulins Drugs 0.000 description 10
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
• 239000002523 lectin Substances 0.000 description 9
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
• 239000013543 active substance Substances 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 235000009582 asparagine Nutrition 0.000 description 8
• 229960001230 asparagine Drugs 0.000 description 8
• 239000013256 coordination polymer Substances 0.000 description 8
• 239000012636 effector Substances 0.000 description 8
• 102000006240 membrane receptors Human genes 0.000 description 8
• 230000009401 metastasis Effects 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 210000004881 tumor cell Anatomy 0.000 description 8
• 108010001857 Cell Surface Receptors Proteins 0.000 description 7
• 239000004472 Lysine Substances 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 102100040247 Tumor necrosis factor Human genes 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 229910052739 hydrogen Inorganic materials 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 102000019034 Chemokines Human genes 0.000 description 5
• 108010012236 Chemokines Proteins 0.000 description 5
• 108090001005 Interleukin-6 Proteins 0.000 description 5
• 108090001007 Interleukin-8 Proteins 0.000 description 5
• 102220551451 Kinetochore scaffold 1_T70A_mutation Human genes 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 239000004268 Sodium erythorbin Substances 0.000 description 5
• 230000001594 aberrant effect Effects 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 229940127089 cytotoxic agent Drugs 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000000539 dimer Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000003814 drug Substances 0.000 description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
• 238000003780 insertion Methods 0.000 description 5
• 230000037431 insertion Effects 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 4
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
• 102000013691 Interleukin-17 Human genes 0.000 description 4
• 108050003558 Interleukin-17 Proteins 0.000 description 4
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 102100023123 Mucin-16 Human genes 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 102100036735 Prostate stem cell antigen Human genes 0.000 description 4
• 101710120463 Prostate stem cell antigen Proteins 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 230000004186 co-expression Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 230000000771 oncological effect Effects 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 235000013930 proline Nutrition 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• JJFQTKHGJJWAJZ-UHFFFAOYSA-N 2-benzylsulfanyl-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1SCC1=CC=CC=C1 JJFQTKHGJJWAJZ-UHFFFAOYSA-N 0.000 description 3
• 102000009075 Angiopoietin-2 Human genes 0.000 description 3
• 108010048036 Angiopoietin-2 Proteins 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 3
• JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 description 3
• 102400001329 Epiregulin Human genes 0.000 description 3
• 101800000155 Epiregulin Proteins 0.000 description 3
• 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 description 3
• 101000845176 Homo sapiens Tsukushi Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 208000005927 Myosarcoma Diseases 0.000 description 3
• 108050003475 Neuregulin Proteins 0.000 description 3
• 102000014413 Neuregulin Human genes 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 208000007452 Plasmacytoma Diseases 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
• 102000007238 Transferrin Receptors Human genes 0.000 description 3
• 108010033576 Transferrin Receptors Proteins 0.000 description 3
• 208000009956 adenocarcinoma Diseases 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 238000006471 dimerization reaction Methods 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
• 239000000710 homodimer Substances 0.000 description 3
• 239000012642 immune effector Substances 0.000 description 3
• 239000000367 immunologic factor Substances 0.000 description 3
• 229940121354 immunomodulator Drugs 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 201000002077 muscle cancer Diseases 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000000770 proinflammatory effect Effects 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 238000009097 single-agent therapy Methods 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000003200 Adenoma Diseases 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 235000002198 Annona diversifolia Nutrition 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
• 229940122494 BTLA agonist Drugs 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 102000003930 C-Type Lectins Human genes 0.000 description 2
• 108090000342 C-Type Lectins Proteins 0.000 description 2
• 102000000905 Cadherin Human genes 0.000 description 2
• 108050007957 Cadherin Proteins 0.000 description 2
• 241000282836 Camelus dromedarius Species 0.000 description 2
• 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
• 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
• 108010009685 Cholinergic Receptors Proteins 0.000 description 2
• 208000005243 Chondrosarcoma Diseases 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 102100034573 Desmoglein-4 Human genes 0.000 description 2
• 101710183213 Desmoglein-4 Proteins 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102100038083 Endosialin Human genes 0.000 description 2
• 101710144543 Endosialin Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
• 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
• 108010008165 Etanercept Proteins 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102100039554 Galectin-8 Human genes 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101000777270 Homo sapiens Calcineurin B homologous protein 3 Proteins 0.000 description 2
• 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
• 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 2
• 101100182729 Homo sapiens LY6K gene Proteins 0.000 description 2
• 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 241000282838 Lama Species 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 2
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
• 102000003735 Mesothelin Human genes 0.000 description 2
• 108090000015 Mesothelin Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 229920000037 Polyproline Polymers 0.000 description 2
• 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
• 101100127442 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mis3 gene Proteins 0.000 description 2
• 101100401689 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mis4 gene Proteins 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
• 102000034337 acetylcholine receptors Human genes 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 238000005277 cation exchange chromatography Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 101150040681 cho1 gene Proteins 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 230000002301 combined effect Effects 0.000 description 2
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• 150000002270 gangliosides Chemical class 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 230000005865 ionizing radiation Effects 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 208000012804 lymphangiosarcoma Diseases 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 208000001611 myxosarcoma Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 208000003154 papilloma Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 108010026466 polyproline Proteins 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 201000006845 reticulosarcoma Diseases 0.000 description 2
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 230000008054 signal transmission Effects 0.000 description 2
• IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 2
• 229950001353 tretamine Drugs 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 229910052720 vanadium Inorganic materials 0.000 description 2
• FBDOJYYTMIHHDH-OZBJMMHXSA-N (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,14,20-heptaen-18-one Chemical compound CC[C@@]1(O)C(=O)OCC2=CN3Cc4cc5ccccc5nc4C3C=C12 FBDOJYYTMIHHDH-OZBJMMHXSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• IRGKJPHTQIWQTD-UHFFFAOYSA-N 2,7-dibromopyrene-1,3,6,8-tetrone Chemical compound O=C1C(Br)C(=O)C2=CC=C3C(=O)C(Br)C(=O)C4=CC=C1C2=C43 IRGKJPHTQIWQTD-UHFFFAOYSA-N 0.000 description 1
• UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
• CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
• KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
• 208000010400 APUDoma Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 208000005034 Angiolymphoid Hyperplasia with Eosinophilia Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 102100034286 Ankyrin repeat domain-containing protein 27 Human genes 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
• 102100032311 Aurora kinase A Human genes 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 230000024704 B cell apoptotic process Effects 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
• 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
• 208000003609 Bile Duct Adenoma Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000000529 Branchioma Diseases 0.000 description 1
• 208000023611 Burkitt leukaemia Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 108050009459 C2 domains Proteins 0.000 description 1
• 102000002110 C2 domains Human genes 0.000 description 1
• 108700012439 CA9 Proteins 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
• 108090000209 Carbonic anhydrases Proteins 0.000 description 1
• 102000003846 Carbonic anhydrases Human genes 0.000 description 1
• 206010007270 Carcinoid syndrome Diseases 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 201000000274 Carcinosarcoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• 101800001545 Cholecystokinin-5 Proteins 0.000 description 1
• 102400000884 Cholecystokinin-5 Human genes 0.000 description 1
• 206010008642 Cholesteatoma Diseases 0.000 description 1
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 229920001287 Chondroitin sulfate Polymers 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000016216 Choristoma Diseases 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 102100023774 Cold-inducible RNA-binding protein Human genes 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 201000005171 Cystadenoma Diseases 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
• 208000005163 Extra-Adrenal Paraganglioma Diseases 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 201000005618 Glomus Tumor Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 239000004471 Glycine Chemical group 0.000 description 1
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000002125 Hemangioendothelioma Diseases 0.000 description 1
• 208000006050 Hemangiopericytoma Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
• 101000780114 Homo sapiens Ankyrin repeat domain-containing protein 27 Proteins 0.000 description 1
• 101000799549 Homo sapiens Aspartate aminotransferase, mitochondrial Proteins 0.000 description 1
• 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
• 101100113588 Homo sapiens CS gene Proteins 0.000 description 1
• 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 1
• 101000906744 Homo sapiens Cold-inducible RNA-binding protein Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 1
• 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
• 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
• 101000801109 Homo sapiens Transmembrane protein 131 Proteins 0.000 description 1
• 101000771675 Homo sapiens WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 241000235789 Hyperoartia Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 108050001157 Link domains Proteins 0.000 description 1
• 102000010954 Link domains Human genes 0.000 description 1
• 102000019298 Lipocalin Human genes 0.000 description 1
• 108050006654 Lipocalin Proteins 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 208000004138 Lymphangiomyoma Diseases 0.000 description 1
• 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 241001076084 Matus Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 208000010153 Mesonephroma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
• 201000004458 Myoma Diseases 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 206010063663 Neuropsychiatric lupus Diseases 0.000 description 1
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
• 206010061876 Obstruction Diseases 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 240000004760 Pimpinella anisum Species 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
• 102100024304 Protachykinin-1 Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
• 208000005678 Rhabdomyoma Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 108010085012 Steroid Receptors Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Chemical group 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102100033700 Transmembrane protein 131 Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 108010056243 alanylalanine Proteins 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 208000010029 ameloblastoma Diseases 0.000 description 1
• 238000010640 amide synthesis reaction Methods 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 201000009431 angiokeratoma Diseases 0.000 description 1
• 208000000252 angiomatosis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000003471 anti-radiation Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
• 239000003435 antirheumatic agent Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
• 229960005207 auranofin Drugs 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 208000021592 benign granular cell tumor Diseases 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 208000002352 blister Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 239000004568 cement Substances 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 201000005217 chondroblastoma Diseases 0.000 description 1
• 229940059329 chondroitin sulfate Drugs 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000003297 denaturating effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 210000003027 ear inner Anatomy 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 201000004260 follicular adenoma Diseases 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 208000030878 follicular thyroid adenoma Diseases 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 201000008361 ganglioneuroma Diseases 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 201000005626 glomangioma Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 239000003316 glycosidase inhibitor Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000002557 hidradenitis Diseases 0.000 description 1
• 201000009379 histiocytoid hemangioma Diseases 0.000 description 1
• 201000000284 histiocytoma Diseases 0.000 description 1
• 102000050629 human TSKU Human genes 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 230000000503 lectinlike effect Effects 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000002332 leydig cell Anatomy 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 201000006812 malignant histiocytosis Diseases 0.000 description 1
• 239000002603 mannosidase inhibitor Substances 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 201000000248 mediastinal malignant lymphoma Diseases 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 210000000716 merkel cell Anatomy 0.000 description 1
• 208000004197 mesenchymoma Diseases 0.000 description 1
• 208000011831 mesonephric neoplasm Diseases 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 201000004130 myoblastoma Diseases 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 208000004128 odontoma Diseases 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 208000007312 paraganglioma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 108091005706 peripheral membrane proteins Proteins 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 150000003148 prolines Chemical class 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 229960001302 ridaforolimus Drugs 0.000 description 1
• WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 102000005969 steroid hormone receptors Human genes 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• 229960000235 temsirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 239000004308 thiabendazole Substances 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
• 229960003107 tramadol hydrochloride Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 150000003918 triazines Chemical class 0.000 description 1
• NFRBUOMQJKUACC-UHFFFAOYSA-N triethyl(pentyl)azanium Chemical compound CCCCC[N+](CC)(CC)CC NFRBUOMQJKUACC-UHFFFAOYSA-N 0.000 description 1
• 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 150000003672 ureas Chemical class 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 229950009819 zotarolimus Drugs 0.000 description 1
• CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
• JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1